Patents Assigned to Children's Medical Center Corporation
  • Patent number: 11180762
    Abstract: Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: November 23, 2021
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Judy Lieberman, Adi Gilboa-Geffen, Lee Adam Wheeler
  • Patent number: 11181594
    Abstract: Systems and methods for analyzing metabolite concentration in a subject using a medical imaging system are provided. The method includes, using a nuclear magnetic resonance (NMR] system, acquiring data from a subject during multiple acquisitions using different echo times for the multiple acquisitions to create a chemical shift domain. The method also includes, using the chemical shift domain, identifying metabolites by at least two chemical shifts and generating a report indicating the metabolites.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: November 23, 2021
    Assignees: BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Alexander Lin, Susan Waisbren
  • Publication number: 20210355210
    Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.
    Type: Application
    Filed: June 10, 2019
    Publication date: November 18, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank
  • Patent number: 11172866
    Abstract: The systems and methods described herein combine both moisture and electromyograph (EMG) sensors in a single wearable garment, along with a suitable output device such as a “smart” mobile device or computer, to provide users with new and useful feedback that can significantly improve incontinence symptoms. The EMG provides feedback to the user specifically regarding the quality of pelvic floor muscle contractions, while the moisture sensor provides feedback about the “end result” of the subjects' incontinence. Each measurement device alone can also provide useful information and feedback to different population groups. Combining these two measurements provides unprecedented data to enhance the subjects' therapy in managing urinary incontinence.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 16, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Jeanne Chow, Carlos Estrada, Michael K. Dempsey
  • Patent number: 11167042
    Abstract: Provided herein are materials and methods for efficiently delivering nucleic acids to cochlear and vestibular cells.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: November 9, 2021
    Assignees: Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute, Children's Medical Center Corporation
    Inventors: Konstantina Stankovic, Luk H. Vandenberghe, Jeffrey Holt, Gwenaelle Geleoc
  • Publication number: 20210338659
    Abstract: Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.
    Type: Application
    Filed: July 26, 2019
    Publication date: November 4, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Bing CHEN, Gary FREY, Tianshu XIAO
  • Publication number: 20210338823
    Abstract: Provided herein, in some aspects, are delivery vehicles comprising a ceramide and an agent to be delivered attached to the ceramide. In some embodiments, the ceramide does not comprise a fatty acid (i.e., is a sphingosine). In some embodiments, the ceramide comprises a fatty acid. In some embodiments, the ceramide is a glycoceramide. In some embodiments, the agent is attached to the ceramide covalently (e.g., via a linker). In some embodiments, the agent to be delivered is a therapeutic agent. The ceramide is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the ceramide described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the ceramide delivery vehicle are also provided.
    Type: Application
    Filed: April 12, 2019
    Publication date: November 4, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Wayne I. Lencer, Daniel JF Chinnapen, Richard I. Duclos
  • Patent number: 11162073
    Abstract: Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonisists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 2, 2021
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
    Inventors: Dhvanit I. Shah, George Q. Daley
  • Publication number: 20210332090
    Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.
    Type: Application
    Filed: July 31, 2020
    Publication date: October 28, 2021
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard MALLEY, Yingjie LU, Fan ZHANG
  • Publication number: 20210330588
    Abstract: Compositions and methods of use related to formulations comprising anesthetics are generally described. Some embodiments are directed to compositions comprising a plurality of micelles and/or particles, and an anesthetic contained internally. These can be used to control and/or prolong the duration of IVRA while reducing the risk of systemic toxicity commonly due to administering anesthetics. The control and/or prolonged duration of IVRA may be due, at least in part, to the attachment of the sufficiently small micelles and/or particles to a biointerface (e.g., blood vessel surface) where the composition has been administered. Conventional IVRA methods commonly do not utilize potent and long-acting anesthetics (e.g., bupivacaine) due to the risks of cardiac toxicity. The compositions and methods described herein, however, provide a pathway for increased safety and efficiency of the use of such anesthetics, in certain embodiments. Resultantly, the performance (e.g.
    Type: Application
    Filed: October 10, 2019
    Publication date: October 28, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Tianjiao Ji, Christopher B. Weldon
  • Patent number: 11155620
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Publication number: 20210324057
    Abstract: Described herein are methods and compositions for treating graft versus host disease. Additionally, described herein are methods and compositions for treating diabetes. Aspects of the invention relates to administering to a subject an agent that inhibits LRRC8A as a monotherapy or in combination with additional therapeutics.
    Type: Application
    Filed: October 25, 2019
    Publication date: October 21, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Janet S. CHOU, Raif S. GEHA
  • Publication number: 20210324024
    Abstract: Provided herein are methods and compositions comprising or using mutant semaphorin polypeptides.
    Type: Application
    Filed: August 27, 2019
    Publication date: October 21, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Diane R. BIELENBERG, Johannes WEDEL
  • Publication number: 20210322396
    Abstract: The present disclosure provides compositions and methods for delivery of therapeutic agents across a barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent, wherein the composition comprises between about 0.5-5.0% wt/vol of a permeation enhancer that is sodium dodecyl sulfate; wherein the compositions comprise between about 0.5-2.5% wt/vol of a permeation enhancer that is bupivacaine; wherein the compositions comprise between about 1.5-12.0% wt/vol of a permeation enhancer that is limonene; and wherein the compositions comprise between about 9.0-19.0% wt/vol of a polymer that is poloxamer 407-poly(butoxy)phosphoester; and optionally further comprises between about 0.01-0.50% wt/vol of another therapeutic agent that is a sodium channel blocker anesthetic agent (e.g., tetrodotoxin).
    Type: Application
    Filed: August 30, 2019
    Publication date: October 21, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Daniel S. Kohane, Rong Yang
  • Patent number: 11147828
    Abstract: The present invention relates to methods to treat or prevent cancers in a subject, in particular the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have reduced expression or are lacking in the cancer stem cells. in some embodiments, the miRNAs that are reduced or lacking in cancer stem cells are let-7 miRNAs. In alternative embodiments, the present invention relates to a method of treating and/or preventing cancer comprising targeting cancer stem cells by administering miRNAs which have increased expression levels in the cancer stem cells. Another aspect of the present invention relates to methods to enrich for a cancer stem cell population. Another aspect of the present invention relates to methods to identify miRNAs which contribute to the self-renewal capacity of cancer stem cells.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 19, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Judy Lieberman, Erwei Song, Fengyan Yu, Xiaoqu Hu
  • Patent number: 11147890
    Abstract: Provided herein are various gas-filled particles having a stimuli-responsive shell encapsulating the gas. The stimuli-responsive shell comprises one or more release triggers. Compositions for medical or non-medical applications, methods of use and treatment, and methods of preparation are also described.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 19, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Brian D. Polizzotti, Yifeng Peng, John Kheir
  • Publication number: 20210315940
    Abstract: Provided herein are methods of using mesenchymal stem cell (MSC) exosomes to treat placental insufficiency and/or infertility in a female subject, and/or treating fetal growth restriction in a fetus.
    Type: Application
    Filed: September 5, 2019
    Publication date: October 14, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Stella Kourembanas, S. Alexander Mitsialis, Elizabeth S. Taglauer
  • Publication number: 20210309970
    Abstract: The invention features methods of identifying a hematopoietic/stem progenitor population for clinical transplantation and gene therapy, and compositions for transplantation or gene therapy featuring cells characterized as CD34+CD164High.
    Type: Application
    Filed: March 26, 2021
    Publication date: October 7, 2021
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: LUCA BIASCO, MARIANA LOPERFIDO, CRISTINA BARICORDI, DANILO PELLIN
  • Patent number: 11136383
    Abstract: Disclosed are compositions and methods for modulating the activity of TGF-?. More particularly, compositions and methods for modulating the release of active TGF-? from an LRRC33-TGF-? prodomain-TGF-? ternary complex are provided, as are and methods of treatment based upon such modulation.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 5, 2021
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Timothy Alan Springer, Chafen Lu, Yan Qin, Aiping Jiang
  • Publication number: 20210299233
    Abstract: Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an asparaginase and an agent that inhibits GSK3f. Another aspect of the invention relates to administering an asparaginase to a subject having cancer that comprises an inactivating mutation in GSK3f.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 30, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Alejandro GUTIERREZ, Laura HINZE